Related Experiment Video

Updated: Sep 26, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

A protein kinase Cbeta inhibitor attenuates multidrug resistance of neuroblastoma cells

Karin Svensson1, Christer Larsson

  • 1Molecular Medicine, Lund Univeristy, Entrance 78, 3rd floor, Malmö University Hospital, SE-205 02 Malmö, Sweden. Karin.J.Svensson@astrazeneca.com

BMC Cancer
|April 17, 2003
PubMed
Abstract

Insights

Inhibiting Protein Kinase C beta (PKCbeta) with LY379196 can overcome drug resistance in neuroblastoma. This approach enhances the effectiveness of certain chemotherapy drugs by increasing their accumulation in resistant cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Neuroblastoma drug resistance significantly impacts patient outcomes.
  • Protein Kinase C (PKC) involvement in cancer drug resistance is suspected.
  • PKCbeta isoforms are potential targets for overcoming neuroblastoma chemoresistance.

Purpose of the Study:

  • To investigate if inhibiting PKCbeta isoforms can reverse drug resistance in neuroblastoma cells.
  • To determine the effect of a specific PKCbeta inhibitor, LY379196, on neuroblastoma chemotherapy sensitivity.

Main Methods:

  • MTT assays were used to assess the impact of LY379196 on neuroblastoma cell growth inhibition by various chemotherapeutics.
  • The accumulation of [3H]vincristine in neuroblastoma cells was measured in the presence of LY379196.
  • Additional PKC inhibitors (Gö6976, GF109203X) were tested for their effects on vincristine sensitivity.

Main Results:

  • The PKCbeta inhibitor LY379196 demonstrated growth-suppressive effects on neuroblastoma cell lines.
  • LY379196 potentiated the efficacy of doxorubicin, etoposide, paclitaxel, and vincristine, but not carboplatin.
  • The most significant enhancement was observed with vincristine in the highly resistant SK-N-BE(2) cell line.
  • PKC inhibitors increased the intracellular accumulation of vincristine in resistant cells.

Conclusions:

  • Inhibition of PKCbeta can attenuate multidrug resistance in neuroblastoma.
  • Augmenting intracellular drug levels by inhibiting PKCbeta may be a strategy to improve chemotherapy outcomes.
  • Targeting PKCbeta offers a potential therapeutic approach for overcoming chemoresistance in neuroblastoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...